Current Report Filing (8-k)
20 Enero 2021 - 4:07PM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-01-20
2021-01-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): January 20, 2021
ADAMIS
PHARMACEUTICALS CORPORATION
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
11682
El Camino Real, Suite 300
San
Diego, CA
|
|
92130
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 997-2400
(Former
name or Former Address, if Changed Since Last Report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
January 20, 2021, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) issued a press
release announcing that it had submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New
Drug (“IND”) application for the investigational use of Tempol, an investigational drug, for the treatment of
Coronavirus (COVID-19). A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated
into this item by reference.
Forward
Looking Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets
or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following statements: the company’s beliefs concerning the safety
and effectiveness of Tempol or the company’s other product candidates; the timing of funding for, or commencement or completion
of, any studies or trials relating to Tempol; the availability of, and the company’s success in applying for and obtaining,
government or other funding for studies or trials relating to Tempol or the timing or amount of any such funding; the results
of any future studies or trials that the company may conduct relating to Tempol; the company’s ability to commercialize
the product candidates described in this Report, itself or through commercialization partners; and other statements concerning
our future operations and activities. These statements are only predictions and involve known and unknown risks, uncertainties
and other factors, which may cause Adamis' actual results to be materially different from the results anticipated by such forward-looking
statements. There can be no assurances regarding the outcome of our submission of the IND relating to investigational use of,
or trials or studies relating to, Tempol, regarding the timing or the outcome of any applications or requests that we may submit
for government or other funding for studies or trials relating to Tempol; concerning the timing or outcome of any such studies
or trials; or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. In addition,
forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to
support such activities and continue our operations and planned activities. As discussed in our filings with the Securities
and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if
required. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue
reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made,
and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions
to these forward-looking statements or to reflect events or circumstances arising after the date of this Report. Certain of these
risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time
to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2019 and subsequent
filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on
the SEC's web site at http://www.sec.gov.
Except to the extent required by law, any forward-looking statements in this Report speak only as the date of this Report, and
Adamis expressly disclaims any obligation to update any forward-looking statements.
Item
9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits.
99.1
|
|
Press
release dated January 20, 2021.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADAMIS
PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated:
January 20, 2021
|
By:
|
/s/ Robert O. Hopkins
|
|
|
Name:
|
Robert
O. Hopkins
|
|
Title:
|
Chief
Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Adamis Pharmaceuticals Corporation (NASDAQ): 0 recent articles
Más de Adamis Pharmaceuticals Corp Artículos de Noticias